Series: The T Files — Series 4: “Gels, Patches & the Skin Transfer Disaster"
Subtitle: The transdermal era promised to fix everything. Then men started accidentally hormoning their wives.
Post: 3 of 5
Tags: AndroGel, testosterone gel, TRT 2000, hydroalcoholic gel, pharmacokinetics, AbbVie, transdermal testosterone, serum testosterone
Word Count: ~1,100
In 2000, AbbVie (then Abbott Laboratories) launched AndroGel in the United States. It was a clear, colorless hydroalcoholic gel containing testosterone. You applied it to your shoulders, upper arms, or abdomen once a day in the morning. It dried in a few minutes. You wore a shirt. You went to work.
No needles. No needles ever again.
AndroGel’s market uptake was rapid. It became the dominant form of TRT in the United States within a few years. By 2012, AbbVie reported US sales of AndroGel exceeding $1 billion annually [IMS Health, 2014]. The testosterone therapy market had been reshaped by a product that — compared to everything that preceded it — was almost embarrassingly easy to use.
Understanding why AndroGel succeeded requires looking at the specific pharmacology that made it different, and understanding why it dominated requires acknowledging how thoroughly it outperformed its predecessors on the metrics that mattered most to patients.
The Chemistry: Why Hydroalcoholic Gels Work
AndroGel is formulated as a testosterone hydroalcoholic gel. The carrier is a mixture of ethanol and water, with testosterone dissolved within it. When the gel is applied to skin, the ethanol rapidly evaporates, leaving a thin testosterone-containing film on the skin surface. The remaining testosterone then slowly penetrates the stratum corneum through passive diffusion.
This mechanism differs meaningfully from the Androderm patch approach. The patch required added permeation enhancers to drive testosterone through skin because the patch’s delivery needed to be sustained over 24 hours from a fixed area. The gel, by contrast, applies testosterone over a relatively large skin surface — the entire shoulder or upper arm region — allowing passive diffusion to work without chemical enhancement. The skin is not forced; it is simply given a favorable concentration gradient and time.
The result, pharmacologically, is a delivery profile that is genuinely continuous and genuinely physiological.
The Pharmacokinetic Data
A pivotal three-month randomized, parallel-group study in 227 hypogonadal men compared AndroGel 1% at 50 mg/day and 100 mg/day against the Androderm patch at 5 mg/day. The results were published and became the foundational PK data for the product.
On day one of the 50 mg/day gel regimen, serum testosterone reached a Cmax of 560 ±31 ng/dL after 22 hours of application. By day 30, with steady-state absorption established, the Cmax in the 50 mg/day group had risen to 875 ±57 ng/dL, with a Cmin of 360 ±39 ng/dL. The higher dose (100 mg/day) produced a steady-state Cmax of 1,198 ±56 ng/dL, with a Cmin of 504 ±27 ng/dL.
Read those trough numbers carefully: 360 ng/dL at 50 mg/day. This is a testosterone level measured at the nadir of a dosing cycle — the lowest point before the next day’s dose — and it is still within the physiological range. Compare this to testosterone enanthate at 400mg every four weeks, where patients were reliably dropping below 300 ng/dL — into clinically hypogonadal territory — before their next injection.
The package insert language for AndroGel 1% describes serum testosterone peaking at 16–22 hours after application and being “absorbed continuously throughout the 24-hour dosing period.” That “absorbed continuously” phrase is the key. There is no bolus injection. There is no dramatic spike. There is a gradual rise to a plateau and a gradual decline — a pharmacokinetic profile that looks, roughly, like what a healthy endocrine system does naturally.
Dosing Flexibility: A Genuine Clinical Advance
One of AndroGel’s meaningful practical advantages was dose adjustability. The 1% concentration was available in 25 mg/2.5 g and 50 mg/5 g unit-dose packets, as well as a metered-dose pump. Doses could be increased in 25 mg increments up to 100 mg/day based on serum testosterone levels measured at 14 and 28 days after initiation.
This titratability mattered clinically. Different men absorb testosterone transdermally at different rates — individual variation in skin thickness, body hair, and skin condition all affect absorption. A therapy that can be adjusted to the individual, rather than forcing the individual to adapt to fixed doses, produces better outcomes. AndroGel’s flexible dosing range was a genuine improvement over the more rigid injection regimens.
The 1.62% concentration, also available as Androgel (but AbbVie’s subsequent formulation), offered a more potent pump — 20.25 mg per actuation — allowing finer dose adjustments between 20.25 and 81 mg/day. Monitoring was recommended at 14 and 28 days after initiation, with dose adjustments targeting serum testosterone between 350 and 750 ng/dL.
Adverse Effects: A Much Better Profile
Compared to Androderm’s 48% application site reaction rate, AndroGel’s skin tolerability was dramatically better. The most common adverse effect of AndroGel 1% was acne, with an incidence of 1–8% depending on the dose — a well-understood testosterone effect, not a formulation-specific skin damage issue. Application site reactions (redness, irritation) occurred in 3–5% of patients — a fraction of the Androderm rate.
For AndroGel 1.62%, the most commonly reported adverse effect in the primary 364-day study was increased PSA level, with an 11.1% incidence using a specific PSA elevation threshold (>4 ng/mL or an increase >0.75 ng/mL on two separate occasions). All other adverse effects were under 3%.
These numbers represent a step-change in tolerability compared to both the patch era and the injection era. The men who had been cycling through injection-site soreness, mood volatility, and pharmacokinetic peaks and troughs now had a once-daily, easily applied, well-tolerated alternative that maintained genuinely physiological serum testosterone.
The Market Result
AndroGel’s rapid dominance of the US TRT market between 2000 and 2010 was not the result of aggressive marketing alone — though the marketing was aggressive. It was the result of a product that was meaningfully better than the alternatives on patient-facing metrics: no injections, no extreme fluctuations, good tolerability, once-daily application.
The subsequent gel products that followed AndroGel into the market — Fortesta (2010), Testim (2002), Vogelxo (2014), and the Axiron underarm solution (2010) — all shared the same fundamental mechanism. Hydroalcoholic carrier. Once-daily. Continuous absorption. All received the same Boxed Warning. Because there was a problem no one had fully anticipated.
When testosterone gel applied to the skin transfers to another person’s skin — and it does transfer, through incidental contact — that person absorbs testosterone too. Children who hugged a treated parent. Partners who shared a bed with someone whose gel hadn’t fully dried. The resulting cases of unexpected testosterone exposure in women and children were documented, reported to the FDA, and triggered one of the more unusual safety warnings in modern pharmaceutical history.
Next time: The FDA Boxed Warning on all testosterone gels — what documented cases of virilization in children and hormonal disruption in women actually looked like, what the warning requires, and what “secondary exposure” means in practice for any patient using a topical testosterone product.
